GlobeNewswire: Nuwellis, Inc. Contains the last 10 of 429 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T23:03:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/07/2842332/0/en/Late-Breaking-Data-Highlighting-Benefits-of-Ultrafiltration-Therapy-Using-the-Aquadex-System-for-Heart-Failure-Patients-was-Presented-at-the-Technology-and-Heart-Failure-Therapeuti.html?f=22&fvtc=4&fvtv=19224Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference2024-03-07T14:08:41Z<![CDATA[- Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failure hospitalizations compared to intravenous loop diuretics- Artificial intelligence and machine learning-based model show that lifestyle and clinical factors can be strong predictors of heart failure events]]>https://www.globenewswire.com/news-release/2024/03/05/2840413/0/en/Nuwellis-Inc-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=19224Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results2024-03-05T13:00:00Z<![CDATA[Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital Accounts Strengthens Its Foundation for Growth, Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital Accounts]]>https://www.globenewswire.com/news-release/2024/02/27/2836073/0/en/Nuwellis-Inc-To-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-5-2024.html?f=22&fvtc=4&fvtv=19224Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 20242024-02-27T14:00:00Z<![CDATA[MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on Tuesday, March 5, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.]]>https://www.globenewswire.com/news-release/2024/02/22/2833606/0/en/Nuwellis-Distribution-Partner-SeaStar-Medical-Receives-FDA-Humanitarian-Device-Exemption-for-Pediatric-Selective-Cytopheretic-Device-Quelimmune.html?f=22&fvtc=4&fvtv=19224Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™2024-02-22T12:58:00Z<![CDATA[MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its distribution partner, SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), has received Humanitarian Device Exemption (HDE) from the U.S. Food and Drug Administration (FDA) for Quelimmune™, its pediatric Selective Cytopheretic Device. Quelimmune provides a new therapy option for children weighing 10 kg or more who have acute kidney injury (AKI) and sepsis or a septic condition requiring continuous kidney replacement therapy (CKRT) in a hospital intensive care unit.]]>https://www.globenewswire.com/news-release/2024/02/20/2832351/0/en/Nuwellis-Inc-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=19224Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-02-20T22:06:53Z<![CDATA[MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective February 20, 2024, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to two individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder-approved equity plan.]]>https://www.globenewswire.com/news-release/2024/02/20/2831872/0/en/Nuwellis-to-Announce-Late-Breaking-Clinical-Data-and-Host-Satellite-Symposium-at-Technology-and-Heart-Failure-Therapeutics-Conference.html?f=22&fvtc=4&fvtv=19224Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference2024-02-20T13:42:52Z<![CDATA[Nuwellis to share three presentations highlighting the company’s Aquadex SmartFlow system Nuwellis to share three presentations highlighting the company’s Aquadex SmartFlow system]]>https://www.globenewswire.com/news-release/2024/02/06/2824381/0/en/New-Case-Series-Demonstrates-Potential-of-Aquadex-Therapy-for-End-Stage-Liver-Disease-Patients-with-Fluid-Overload.html?f=22&fvtc=4&fvtv=19224New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload2024-02-06T14:00:00Z<![CDATA[Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don’t respond to diuretics Early findings suggest Aquadex as a potential solution to safely and effectively remove fluid volume for liver disease patients who don’t respond to diuretics]]>https://www.globenewswire.com/news-release/2024/01/04/2804291/0/en/Nuwellis-Receives-FDA-Clearance-for-an-Additional-Dual-Lumen-Extended-Length-Peripheral-Catheter.html?f=22&fvtc=4&fvtv=19224Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter2024-01-04T20:05:13Z<![CDATA[Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies Specialty catheter provides alternative peripheral access for ultrafiltration therapy across a greater range of patient physiologies]]>https://www.globenewswire.com/news-release/2023/11/28/2786898/0/en/New-Real-World-Data-Highlight-the-Clinical-Benefits-of-Ultrafiltration-Therapy-with-Hematocrit-Monitoring-for-Pediatric-Patients.html?f=22&fvtc=4&fvtv=19224New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients2023-11-28T13:00:00Z<![CDATA[The data demonstrate that the hematocrit sensor within the Nuwellis Aquadex® system offers unique advantages for fluid overloaded small patients The data demonstrate that the hematocrit sensor within the Nuwellis Aquadex® system offers unique advantages for fluid overloaded small patients]]>https://www.globenewswire.com/news-release/2023/11/14/2780569/0/en/Nuwellis-Inc-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=19224Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-11-14T21:30:00Z<![CDATA[MINNEAPOLIS, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective November 14, 2023, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to five individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder-approved equity plan.]]>